ArticleMolecular cancer research : MCR2020
Mesenchymal and MAPK Expression Signatures Associate with Telomerase Promoter Mutations in Multiple Cancers.
Open access · bronzeAbstract read
In one paragraph
Article in Molecular cancer research : MCR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 34 citations in OpenAlex.
- Calcifying nested stromal-epithelial tumor of the liver: Report of two cases revealing novel WT1 mutation and distinct epigenetic features.Virchows Archiv : an international journal of pathology · 2026Article
- The -124C>T Mutation of theCurrent oncology (Toronto, Ont.) · 2025Article
- The immortality mechanism of TERT promoter mutant cancers is self-reinforcing and reversible.Molecular cell · 2025Article
- SNAI2 cooperates with MEK1/2 and HDACs to suppress BIM- and BMF-dependent apoptosis in TERT promoter mutant cancers.PloS one · 2025Article
- Quantifying TERT promoter mutations in tumor-derived DNA shed into the oral cavity as a potential biomarker for oral squamous cell carcinoma.Frontiers in oncology · 2025Article
- The regulations of telomerase reverse transcriptase (TERT) in cancer.Cell death & disease · 2024Review
- TERT Promoter Mutations Frequency Across Race, Sex, and Cancer Type.The oncologist · 2024Observational
- Pan-cancer experimental characteristic of human transcriptional patterns connected with telomerase reverse transcriptase (Frontiers in genetics · 2024Article
- Predicting Outcomes of Atezolizumab and Bevacizumab Treatment in Patients with Hepatocellular Carcinoma.International journal of molecular sciences · 2023Review
- AST-487 Inhibits RET Kinase Driven TERT Expression in Bladder Cancer.International journal of molecular sciences · 2022Article
- Mutations in the telomerase reverse transcriptase promoter and PIK3CA gene are common events in penile squamous cell carcinoma of Italian and Ugandan patients.International journal of cancer · 2022Article
- TRIM28 is a transcriptional activator of the mutant TERT promoter in human bladder cancer.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Article
- Cancer-specific loss ofProceedings of the National Academy of Sciences of the United States of America · 2021Article
- Basal Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches.Biomedicines · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Josh Lewis SternBioFrontiers Institute and the Department of Biochemistry, Howard Hughes Medical Institute, University of.ORCID 0000-0002-0588-1586
Grace HibshmanBioFrontiers Institute and the Department of Biochemistry, Howard Hughes Medical Institute, University of.ORCID 0000-0002-3470-4861
Kevin HuDivision of Hematology/Oncology, Department of Medicine, Helen Diller Family Cancer Center; Bakar Computational Health Sciences Institute, Institute of Human Genetics, University of California San Francisco, San Francisco, California.ORCID 0000-0002-3631-8294
Sarah E FerraraUniversity of Colorado Comprehensive Cancer Center, Aurora, Colorado.
James C CostelloUniversity of Colorado, Anschutz Medical Campus, Department of Pharmacology, University of Colorado Comprehensive Cancer Center, Aurora, Colorado.ORCID 0000-0003-3158-9682
William KimDivision of Medical Genetics and Center for Cancer Target Discovery and Development (CTD), Moores Cancer Center, University of California San Diego, La Jolla, California.ORCID 0000-0002-3021-7193
Pablo Tamayo *Division of Medical Genetics and Center for Cancer Target Discovery and Development (CTD), Moores Cancer Center, University of California San Diego, La Jolla, California. pablo.tamayo@ucsd.edu thomas.cech@colorado.edu franklin.huang@ucsf.edu.
Thomas R Cech *BioFrontiers Institute and the Department of Biochemistry, Howard Hughes Medical Institute, University of pablo.tamayo@ucsd.edu thomas.cech@colorado.edu franklin.huang@ucsf.edu.ORCID 0000-0001-7338-3389
Franklin W Huang *Division of Hematology/Oncology, Department of Medicine, Helen Diller Family Cancer Center; Bakar Computational Health Sciences Institute, Institute of Human Genetics, University of California San Francisco, San Francisco, California. pablo.tamayo@ucsd.edu thomas.cech@colorado.edu franklin.huang@ucsf.edu.
Howard Hughes Medical Institute · USNational Foundation for Cancer Research · USUCSF Helen Diller Family Comprehensive Cancer Center · USUniversity of Colorado Cancer Center · US
Funding
University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0MResearch on Prostate Cancer in Men of African Ancestry: Defining the Roles of Genetics, Immunity and Stress (RESPOND)U19CA214253 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HAIMAN, CHRISTOPHER ALAN · 2018 to 2023
$16.8MUsing Networks to Seed Hierarchical Whole-cell Models of CancerU54CA209891 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI IDEKER, TREY, KROGAN, NEVAN J · 2017 to 2021
$10.9MSupporting Integrative Genomic Analysis Users with GenePatternR01GM074024 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MESIROV, JILL P. · 2005 to 2019
$6.6MA Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic StatesU01CA217885 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI COHEN, EZRA, KAUFMAN, DAN S. · 2017 to 2021
$5.1MGenePattern and GenePattern Notebook: Integrative 'Omic Analysis for Cancer ResearchU24CA248457 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MESIROV, JILL P., TAMAYO, PABLO · 2020 to 2024
$4.6MNext-generation Functional Genetic Screening of Un-screenable TraitsR01HG009285 · NHGRI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MALI, PRASHANT, TAMAYO, PABLO · 2017 to 2020
$4.2MSupporting and evolving Gene Set Enrichment Analysis and the Molecular Signatures Database for cancer researchU24CA220341 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MESIROV, JILL P., TAMAYO, PABLO · 2018 to 2022
$3.4MPrecision Interception of Aggressive Prostate Cancer in African American MenP20CA233255 · NCI · DANA-FARBER CANCER INST · PI REBBECK, TIMOTHY R · 2018 to 2020
$3.2MGenePattern Notebooks for Cancer ResearchU24CA194107 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MESIROV, JILL P. · 2015 to 2019
$2.8MMolecular Signatures to Characterize the Oncogenic State of Individual TumorsR01CA154480 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TAMAYO, PABLO · 2011 to 2015
$2.0MRole of PTEN and PI-3 Kinase in MedulloblastomagenesisR01CA172513 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI DURDEN, DONALD · 2017 to 2023
$1.6MHoward Hughes Medical InstituteNCI NIH HHS P20 CA233255NCI NIH HHS P30 CA046934NCI NIH HHS R01 CA154480NCI NIH HHS R01 CA172513NCI NIH HHS U01 CA217885NCI NIH HHS U19 CA214253NCI NIH HHS U24 CA194107NCI NIH HHS U24 CA220341NCI NIH HHS U24 CA248457NCI NIH HHS U54 CA209891NHGRI NIH HHS R01 HG009285NIGMS NIH HHS R01 GM074024NIGMS NIH HHS R01 GM099705
Abstract
In a substantial fraction of cancers
Indexed as
MutationCell Line, TumorChromatin ImmunoprecipitationEpithelial-Mesenchymal TransitionExtracellular Signal-Regulated MAP KinasesGene Expression ProfilingGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansNeoplasmsPromoter Regions, GeneticSequence Analysis, RNASmall Molecule LibrariesTelomeraseTumor MicroenvironmentExtracellular Signal-Regulated MAP KinasesSmall Molecule LibrariesTelomeraseTERT protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.